Back to Search
Start Over
Chimeric antigen receptor T‐cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
- Source :
-
European Journal of Haematology . Feb2024, Vol. 112 Issue 2, p197-210. 14p. - Publication Year :
- 2024
-
Abstract
- The success of chimeric antigen receptor T‐cell (CAR‐T) therapy in hematologic malignancies has realized a longstanding effort toward harnessing the immune system to fight cancer in a truly personalized fashion. Second generation chimeric antigen receptors (CAR) incorporating co‐stimulatory molecules like 4‐1BB or CD28 were able to overcome some of the hindrances with initial CAR constructs resulting in efficacious products. Many second‐generation CAR‐T products have been approved in the treatment of relapsed/refractory hematologic malignancies including multiple myeloma (MM), non‐Hodgkin lymphoma (NHL), and acute lymphoblastic leukemia. However, challenges remain in optimizing the manufacturing, timely access, limiting the toxicity from CAR‐T infusions and improving sustainability of responses derived with CAR‐T therapy. Here, we summarize the clinical trial data leading to approval CAR‐T therapies in MM and NHL, discuss the limitations with current CAR‐T therapy strategies and review emerging strategies for overcoming these limitations. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 09024441
- Volume :
- 112
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- European Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 174818902
- Full Text :
- https://doi.org/10.1111/ejh.14074